Study of DNL628 for people with early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an experimental drug, DNL628, to see if it is safe and how it affects people with early Alzheimer's disease. It may help slow the disease by targeting a specific process in the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 50 and 90 years old (exact age range not specified, but typical for early Alzheimer's studies).
- You have a diagnosis of probable Alzheimer's dementia with mild symptoms (CDR global score 0.5 or 1 and MMSE score 20 to 30).
- You must have a BMI between 18 and 32 and weigh at least 45 kg (about 99 lbs).
- You must have evidence of amyloid plaques in the brain (from past tests or a screening test).
- You cannot have had a prior stroke, significant head injury, or other brain disorder besides Alzheimer's.
- You cannot have received any anti-amyloid or anti-tau immunotherapy (like a vaccine or antibody treatment) before, except for a specific exception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called DNL921 in healthy volunteers and in people with mild to moderate Alzheimer's disease. The goal is to see if it is safe and how the body handles it, which is a first step in finding a new treatment.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
Hear when a new Alzheimer Disease, Early Onset trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.